Compare · DSGN vs NVO
DSGN vs NVO
Side-by-side comparison of Design Therapeutics Inc. (DSGN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DSGN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.77B, about 301.8x DSGN ($652.1M).
- Over the past year, DSGN is up 152.6% and NVO is down 40.3% - DSGN leads by 193.0 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 6 for DSGN).
- NVO has more recent analyst coverage (25 ratings vs 15 for DSGN).
- Company
- Design Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $10.15-2.92%
- $43.38-1.52%
- Market cap
- $652.1M
- $196.77B
- 1M return
- -23.59%
- -1.00%
- 1Y return
- +152.61%
- -40.35%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 11
- Recent ratings
- 15
- 25
Design Therapeutics Inc.
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DSGN
- Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
- SEC Form 8-K filed by Design Therapeutics Inc.
- Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
- Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.
- Cantor Fitzgerald initiated coverage on Design Therapeutics
- SEC Form 10-Q filed by Design Therapeutics Inc.
- Design Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
- SEC Form DEFA14A filed by Design Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates